Technical Data
Pericentrin (Kendrin, Pericentrin-B, PCNT, KIAA0402, PCNT2)
Pericentrin binds to calmodulin and is expressed in the centrosome that serves as a multifunctional scaffold for anchoring proteins and protein complexes. Evidence suggests that pericentrin plays a role in microtubule nucleation and spindle organization. Recent studies show pericentrin plays a role in Majewski/micorcephalic osteodysplastic primordial dwarfism type II (MOPDII) and Seckel Syndrome. Recent use in network modeling indicates a direct link between breast cancer susceptibility to centrosome defects. Pericentrin is a potential marker for centrosome defects in cancer and cancer progression, as centrosomal abonormalities in solid tumors are accompanied by increased pericentrin levels and defects in pericentrin organization.

Suitable for use in Western Blot and Immunocytochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 0.5ug/ml
Immunocytochemistry: 1:500
Optimal dilutions to be determined by the researcher.

Positive Control:
HeLa cell lysate

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabAffinity Purified
100ug-20CBlue IceHumanRabbit
Synthetic linear peptide corresponding to human Pericentrin (KLH).
Purified by immunoaffinity chromatography.
Supplied as a liquid in 0.1M Tris-glycine, pH 7.4, 150mM sodium chloride, 0.05% sodium azide.
Recognizes human Pericentrin. Species sequence homology: Mouse (89%).
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Delaval, B., et al. (2010). J Cell Biol. 188(2): 181-190. 2. Griffith E., et al. (2008). Nat Genet. 40(2): 232- 236. 3. Rauch, A., et al. (2008). Science. 319(5864): 816-819. 4. Pujana, M.A., et al. (2007). Nat Genet. 39(11): 1338-1349. 5. Wen, Y., et al. (2008). J Biol Chem. 283(5): 2793-2803.